Veru Q2 2023 Earnings Report

Veru EPS Results

• Actual EPS: -$0.44
• Consensus EPS: -$0.33
• Beat/Miss: Missed by -$0.11
• One Year Ago EPS: N/A

Veru Revenue Results

• Actual Revenue: $6.59 million
• Expected Revenue: $3.97 million
• Beat/Miss: Beat by +$2.62 million
• YoY Revenue Growth: N/A

Veru Announcement Details

• Quarter: Q2 2023
• Date: 5/11/2023
• Time: N/A

Veru (NASDAQ:VERU), a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.